Penny NASDAQ: BBI finally surpasses a $2 ceiling and heads to $3 after months of decline since mid-February. Brickell Biotech has been developing effective therapeutics for skin diseases for several years. Just hours ago, the company announced positive phase 3 pivotal study results Sofpironium Bromide. Thus, the stock jumped from $1.26 to $3.10 (in pre-market at 7:03 AM EDT).
Q1 2020 revenue is among the highest ever quarterly revenues that Brickell Biotech could achieve in recent years. Moreover, its Q1 2020 cost of revenue was cut by half to make the negative operating income closer to zero. Only huge revenue is needed to deliver significant earnings to dividend-focused stockholders.